Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · EXAGEN INC. (XGN)

Exagen Q2 revenue rises 16% to $19.9 million; full-year revenue guidance raised

Positive Impact 4 of 5 guidance Written later

Exagen reported second-quarter 2026 revenue of $19.9 million, up 16% from $17.2 million a year earlier, and a net loss of $3.2 million, down from $4.4 million. The company also raised its full-year 2026 revenue guidance to $72 million-$75 million from $70 million-$73 million, which signals higher expected sales for the year.

Key points

  • Q2 2026 revenue was $19.9 million, up from $17.2 million in Q2 2025.
  • Net loss narrowed to $3.2 million from $4.4 million, which the company describes as a reduction of nearly 30%.
  • Adjusted EBITDA loss was $0.1 million, compared with $1.7 million a year earlier.
  • Full-year 2026 revenue guidance raised to $72 million-$75 million from $70 million-$73 million; cash and cash equivalents were $24.6 million at June 30, 2026.

The filing

CompanyEXAGEN INC. (XGN)
Form8-K, current report
Filed with the SECAug 4, 2026, 8:02 AM ET
Accession number0001274737-26-000047

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.